ArticleJournal of natural medicines2026
Olive (Olea europaea) phenolics for the control of psoriasis via targeting SMYD2 and IL-17A protein-protein interaction networks.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated skin disease characterized by keratinocyte hyperproliferation and persistent inflammation driven by cytokines signaling. This study aimed to identify novel anti-psoriasis natural products and evaluate their potential molecular attributes. Transcriptomics analysis of psoriatic lesions (GSE54456) and in vitro IL-17A-stimulated HaCaT keratinocytes demonstrated significant upregulation of the lysine methyltransferase SMYD2, suggesting its possible involvement in psoriasis pathology. Treatments of HaCaT cells in vitro with the olive tree (Olea europaea) fruit oil phenolics S-(–)-oleocanthal (OC), S-(–)-hydroxy-oleocanthal (HOC, oleacein), and S-(–)-ligstroside aglycone (LA) at a single 10 µM treatment concentration significantly suppressed the SMYD2 expression and reduced markers of psoriatic inflammation, validated by quantitative PCR and Western blot analysis. The RAW 264.7 macrophages stimulated with LPS and IFN-γ exhibited diminished expression of the pro-inflammatory cytokines, including iNOS, IL-6, and TNF-α, following OC, HOC, and LA treatments. Molecular and protein-protein interaction modeling identified the IL-17A dimer selective binding pocket where OC displayed near-benchmark complementarity binding to the co-crystallized ligand (PubChem CID 153616520), engaging key residues Gln94, Trp67, and Leu97. OC induced the largest pocket expansion (1.52-fold) among all ligands, suggesting strong allosteric interference with IL-17RA binding. Consistently, AlphaLISA assays confirmed the OC ability to effectively inhibit the IL-17A–IL-17RA interaction, unlike LA, which showed modest inhibition. Further, surface plasmon resonance demonstrated dose-dependent blockade of IL-17A–IL-17F binding by OC, validating its IL-17A-IL-17F protein-protein heterodimerization interaction inhibitory capacity. Collectively, findings identify OC as a potent natural modulator for the IL-17 signaling that downregulates SMYD2 and disrupts IL-17A protein-protein interactions, evidencing its anti-psoriatic therapeutic potential.
Indexed as
Identifiers
41796422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.